Developer docs
API playgroundTry for free, no card

Search company profiles

Microbiotix

Full company profile

uuid0002ow1

Namestring
Microbiotix
Legal namestring
Microbiotix, Inc.
Websiteurl
microbiotix.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Microbiotix, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 1998 and headquartered in Worcester, Massachusetts, that discovers and develops proprietary small-molecule drugs targeting serious infectious diseases and multi-drug resistant pathogens. The company's pipeline spans six distinct programs: MBX-400 (filociclovir), a nucleoside analog acting as a dual DNA polymerase/UL97 kinase inhibitor for human cytomegalovirus (CMV) in immunosuppressed transplant recipients and a separate ophthalmic application in adenoviral conjunctivitis; spectinamides, narrow-spectrum semisynthetic spectinomycin analogs for MDR/XDR tuberculosis; aminospectinomycins, broad-spectrum spectinomycin derivatives active against drug-resistant Gram-positive and Gram-negative species including N. gonorrhoeae and biodefense pathogens; type III secretion system (T3SS) inhibitors targeting P. aeruginosa virulence factors for ventilator-associated pneumonia; trans-translation inhibitors exploiting a pathway conserved across >99.9% of bacterial genomes and absent in humans; and RND efflux pump inhibitors (pyranopyridines) intended as combination therapy for carbapenem-resistant Enterobacteriaceae. MBX-400 has completed Phase 1 clinical testing and is reported to be more than five times more potent than the current Valcyte gold standard.

The company is pre-revenue and does not sell commercial products; its economics are driven almost entirely by non-dilutive grant funding and milestone-based research awards rather than product sales. Primary funders include NIAID (over $12 million awarded in 2022 with potential total of approximately $61.5 million over five years for antiviral development targeting pandemic viruses), CARB-X (up to $48 million committed, including a $3.2 million initial award in 2017 and a follow-on 2020 award for an MDR-gonorrhea oral antibiotic), the U.S. Department of Defense for biodefense-relevant programs, and the UK-based AMR Centre, with which Microbiotix maintains a co-development relationship on its anti-virulence P. aeruginosa candidate. Microbiotix has been ranked the top NIH award recipient among Massachusetts biotech/pharma companies in 2020, 2017, 2016, 2015, and 2013, and second in 2019, 2018, and 2014.

The company serves a defined patient population: immunocompromised transplant recipients at risk of CMV (over 33,000 solid organ transplants annually in the U.S. and 126,670 worldwide), patients infected with CDC/WHO urgent-threat pathogens including CRE, drug-resistant N. gonorrhoeae, and MDR/XDR tuberculosis, and patients with adenoviral conjunctivitis for which no approved antiviral currently exists. Its commercial go-to-market is undefined because no product is approved; future commercialization would proceed through traditional pharmaceutical distribution channels following FDA approval. The company employs 11-50 people, is led by President & CEO Terry L. Bowlin, PhD (30+ years of anti-infective experience at BioChem Pharma and Marion Merrell Dow), Chief Business Officer Richard Gauthier, and Chief Scientific Officer Zachary D. Aron, and operates from a single U.S. site with R&D and clinical activities distributed through grant-funded partnerships.

Short descriptiontext

Microbiotix is a privately held, clinical-stage biopharmaceutical company developing proprietary small-molecule drugs for serious infectious diseases and multi-drug resistant pathogens, including CMV in transplant recipients, MDR/XDR tuberculosis, drug-resistant gonorrhea, carbapenem-resistant Enterobacteriaceae, and biodefense pathogens.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWorcester, United States
HQ citystring
Worcester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral drug development, antibiotic drug discovery, multi-drug resistant pathogens, clinical-stage biopharmaceuticals, small molecule therapeutics
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MBX-400 (filociclovir)
Description

Lead therapeutic compound, a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). Previously known as cyclopropavir.

microbiotix.com
+2 more records
Core offering1 text field

Microbiotix discovers and develops proprietary small molecule therapeutics for serious infectious diseases, with a pipeline that includes MBX-400 (filociclovir) for human cytomegalovirus, antibacterial programs (Spectinamides, Aminospectinomycins) for drug-resistant tuberculosis and gonorrhea, T3SS inhibitors for Pseudomonas aeruginosa, trans-translation inhibitors with broad-spectrum activity, and RND efflux pump inhibitors for Enterobacteriaceae. The company is pre-revenue and supports development primarily through grant funding from NIAID/NIH, CARB-X, and the U.S. Department of Defense.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • MBX-400 demonstrated >5x more potent than current gold standard therapy (Valcyte) for CMV treatment
+5 more records
Product overview1 text field

Microbiotix is a clinical stage biopharmaceutical company developing a portfolio of proprietary small molecule drugs targeting serious infectious diseases and multi-drug resistant pathogens. The company's pipeline includes MBX-400 (filociclovir) for CMV infections in transplant recipients and adenoviral conjunctivitis, multiple MDR antibacterial programs including spectinamides and aminospectinomycins for tuberculosis and STDs, T3SS inhibitors for Pseudomonas aeruginosa, trans-translation inhibitors with broad-spectrum activity, and efflux pump inhibitors for Enterobacteriaceae. The company operates through strong partnerships with CARB-X, AMR Centre, NIAID, and DoD.

Product and service7 records
1MBX-400 (filociclovir)
CategoryAntiviral drug candidate (CMV)
Description

Proprietary nucleoside analog that uniquely inhibits both CMV DNA polymerase and UL97 kinase, developed for treatment of human cytomegalovirus infection in immunocompromised solid organ and bone marrow transplant recipients. Reported to be >5x more potent than Valcyte, active against resistant isolates, and non-genotoxic. Has completed Phase 1 clinical testing.

2MBX-400 for Adenoviral Conjunctivitis
CategoryAntiviral drug candidate (adenovirus)
Description

Antiviral application of the MBX-400 platform targeting adenoviral conjunctivitis, including epidemic keratoconjunctivitis, where no approved antiviral therapy currently exists. Demonstrates broad-spectrum efficacy against multiple adenoviral serotypes and is in preclinical development.

3Spectinamides
CategoryAntibacterial drug candidate (tuberculosis)
Description

Novel semisynthetic spectinomycin analogs that inhibit bacterial protein synthesis by binding to a unique site on the 30S ribosome, developed for narrow-spectrum treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. Demonstrated efficacy in multiple in vivo TB infection models.

4Aminospectinomycins
CategoryAntibacterial drug candidate (STIs and biodefense)
Description

Novel spectinomycin derivatives with improved potency against Gram-negative and Gram-positive species, including drug-resistant clinical pathogens such as Neisseria gonorrhoeae and Chlamydia trachomatis, plus biodefense pathogens. Resistance mutants arise at very low frequency (~10^-11) and no cross-resistance is observed against existing protein synthesis inhibitors.

5Type III Secretion System (T3SS) Inhibitors
CategoryAnti-virulence drug candidate (Gram-negative)
Description

Novel anti-virulence small molecules targeting PscF in the Type III Secretion System of Pseudomonas aeruginosa. Reverses pathogen disruption of host innate immune response and is not subject to efflux or existing antibiotic resistance mechanisms. Being developed for prevention and treatment of ventilator-associated pneumonia in critically ill patients.

6Trans-translation Inhibitors
CategoryAntibacterial drug candidate (broad-spectrum)
Description

Broad-spectrum Gram-positive and Gram-negative antibacterial candidates that target the trans-translation pathway, a mechanism conserved across >99.9% of sequenced bacterial genomes and absent in metazoans. Demonstrated in vitro and in vivo activity against MRSA, Neisseria gonorrhoeae, Mycobacterium tuberculosis, and Francisella tularensis.

7Efflux Pump Inhibitors (Pyranopyridines)
CategoryAntibiotic adjuvant / resistance breaker
Description

Novel pyranopyridine RND-type efflux pump inhibitors designed to be used in combination with FDA-approved antibiotics to increase antibacterial potency and decrease resistance mutations in Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The AMR Centre is a key part of the UK's response to the global threat from antimicrobial resistance. Based at Alderley Park, the AMR Centre is a joint private-public initiative supporting the development of new antibiotics and diagnostics through a fully integrated development capability from pre-clinical hits through clinical proof of concept. Microbiotix and the AMR Centre combined resources and antimicrobial R&D expertise to accelerate development of Microbiotix's lead bacterial anti-virulence candidate targeting drug-resistant P. aeruginosa in critically ill pneumonia patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing anti-infectives, including antivirals and antifungal agents. Comparable as a small-cap private/clinical anti-infective developer pursuing novel mechanisms against serious infections, with similar funding-stage profile.

TypeDirect peer
Description

Specialty anti-infective developer focused on tetracycline-class antibiotics for serious community-acquired infections. Comparable as a small-cap clinical-stage antibiotic developer targeting multi-drug resistant pathogens, with overlapping federal funding and NIH grant relationships.

3Nabriva Therapeutics
TypeDirect peer
Description

Clinical-stage biopharma developing antibiotics for serious and life-threatening infections, including MDR pathogens. Directly comparable as a small anti-infective company with a clinical-stage pipeline targeting resistant bacterial infections.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, including oral antibiotics for complicated UTIs. Comparable in therapeutic area (MDR infections), stage, and small-cap funding model.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing differentiated antibiotics for drug-resistant Gram-negative infections. Directly comparable as a focused anti-infective developer with a similar target pathogen profile (CRE, MDR Pseudomonas).

TypeDirect peer
Description

Private clinical-stage biopharmaceutical company developing novel antibiotics to treat MDR Gram-negative infections. Comparable in therapeutic focus (MDR bacterial infections), company stage, and BARDA-funded development model.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company that developed eravacycline, a fluorocycline antibiotic for MDR infections (now part of Innoviva). Comparable as a historical peer in clinical-stage antibiotic development targeting serious multi-drug resistant infections.

TypeDirect peer
Description

Commercial-stage anti-infective company that developed antibiotics for MDR bacterial infections before restructuring. Comparable as a historical peer in the antibiotic development space targeting MDR pathogens, illustrating both the opportunity and the structural commercial challenges.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing ridinilazole for C. difficile infection and other anti-infective candidates. Comparable as a clinical-stage anti-infective developer focused on novel mechanisms against serious bacterial infections.

TypeDirect peer
Description

Former commercial-stage antibiotic developer (plazomicin for CRE) that filed for bankruptcy post-approval. Comparable as a historical direct peer that pursued a similar MDR Gram-negative pathogen strategy and illustrates the commercial risks facing Microbiotix's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microbiotix

Infectious Disease Therapeuticsmicrobiotix.com

Microbiotix is a privately held, clinical-stage biopharmaceutical company developing proprietary small-molecule drugs for serious infectious diseases and multi-drug resistant pathogens, including CMV in transplant recipients, MDR/XDR tuberculosis, drug-resistant gonorrhea, carbapenem-resistant Enterobacteriaceae, and biodefense pathogens.

What Microbiotix does

Microbiotix, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 1998 and headquartered in Worcester, Massachusetts, that discovers and develops proprietary small-molecule drugs targeting serious infectious diseases and multi-drug resistant pathogens. The company's pipeline spans six distinct programs: MBX-400 (filociclovir), a nucleoside analog acting as a dual DNA polymerase/UL97 kinase inhibitor for human cytomegalovirus (CMV) in immunosuppressed transplant recipients and a separate ophthalmic application in adenoviral conjunctivitis; spectinamides, narrow-spectrum semisynthetic spectinomycin analogs for MDR/XDR tuberculosis; aminospectinomycins, broad-spectrum spectinomycin derivatives active against drug-resistant Gram-positive and Gram-negative species including N. gonorrhoeae and biodefense pathogens; type III secretion system (T3SS) inhibitors targeting P. aeruginosa virulence factors for ventilator-associated pneumonia; trans-translation inhibitors exploiting a pathway conserved across >99.9% of bacterial genomes and absent in humans; and RND efflux pump inhibitors (pyranopyridines) intended as combination therapy for carbapenem-resistant Enterobacteriaceae. MBX-400 has completed Phase 1 clinical testing and is reported to be more than five times more potent than the current Valcyte gold standard.

The company is pre-revenue and does not sell commercial products; its economics are driven almost entirely by non-dilutive grant funding and milestone-based research awards rather than product sales. Primary funders include NIAID (over $12 million awarded in 2022 with potential total of approximately $61.5 million over five years for antiviral development targeting pandemic viruses), CARB-X (up to $48 million committed, including a $3.2 million initial award in 2017 and a follow-on 2020 award for an MDR-gonorrhea oral antibiotic), the U.S. Department of Defense for biodefense-relevant programs, and the UK-based AMR Centre, with which Microbiotix maintains a co-development relationship on its anti-virulence P. aeruginosa candidate. Microbiotix has been ranked the top NIH award recipient among Massachusetts biotech/pharma companies in 2020, 2017, 2016, 2015, and 2013, and second in 2019, 2018, and 2014.

The company serves a defined patient population: immunocompromised transplant recipients at risk of CMV (over 33,000 solid organ transplants annually in the U.S. and 126,670 worldwide), patients infected with CDC/WHO urgent-threat pathogens including CRE, drug-resistant N. gonorrhoeae, and MDR/XDR tuberculosis, and patients with adenoviral conjunctivitis for which no approved antiviral currently exists. Its commercial go-to-market is undefined because no product is approved; future commercialization would proceed through traditional pharmaceutical distribution channels following FDA approval. The company employs 11-50 people, is led by President & CEO Terry L. Bowlin, PhD (30+ years of anti-infective experience at BioChem Pharma and Marion Merrell Dow), Chief Business Officer Richard Gauthier, and Chief Scientific Officer Zachary D. Aron, and operates from a single U.S. site with R&D and clinical activities distributed through grant-funded partnerships.

Microbiotix firmographics

Firmographics
Name
Microbiotix
Legal name
Microbiotix, Inc.
Website
https://microbiotix.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Microbiotix is a privately held, clinical-stage biopharmaceutical company developing proprietary small-molecule drugs for serious infectious diseases and multi-drug resistant pathogens, including CMV in transplant recipients, MDR/XDR tuberculosis, drug-resistant gonorrhea, carbapenem-resistant Enterobacteriaceae, and biodefense pathogens.
Ownership category
akta.pro rank

Microbiotix industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antiviral drug development
  • Antibiotic drug discovery
  • Multi-drug resistant pathogens
  • Clinical-stage biopharmaceuticals
  • Small molecule therapeutics

Where Microbiotix is headquartered

Location

Headquarters

HQ city
Worcester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Microbiotix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Marketing channels3 records

Microbiotix product offering

Product offering

Core offering

Microbiotix discovers and develops proprietary small molecule therapeutics for serious infectious diseases, with a pipeline that includes MBX-400 (filociclovir) for human cytomegalovirus, antibacterial programs (Spectinamides, Aminospectinomycins) for drug-resistant tuberculosis and gonorrhea, T3SS inhibitors for Pseudomonas aeruginosa, trans-translation inhibitors with broad-spectrum activity, and RND efflux pump inhibitors for Enterobacteriaceae. The company is pre-revenue and supports development primarily through grant funding from NIAID/NIH, CARB-X, and the U.S. Department of Defense.

Product overview

Microbiotix is a clinical stage biopharmaceutical company developing a portfolio of proprietary small molecule drugs targeting serious infectious diseases and multi-drug resistant pathogens. The company's pipeline includes MBX-400 (filociclovir) for CMV infections in transplant recipients and adenoviral conjunctivitis, multiple MDR antibacterial programs including spectinamides and aminospectinomycins for tuberculosis and STDs, T3SS inhibitors for Pseudomonas aeruginosa, trans-translation inhibitors with broad-spectrum activity, and efflux pump inhibitors for Enterobacteriaceae. The company operates through strong partnerships with CARB-X, AMR Centre, NIAID, and DoD.

Differentiator

Problem solved

Functional benefit

Brands

  • MBX-400 (filociclovir): Lead therapeutic compound, a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). Previously known as cyclopropavir.
  • Spectinamides
  • Aminospectinomycins

Products and services

  • MBX-400 (filociclovir) Proprietary nucleoside analog that uniquely inhibits both CMV DNA polymerase and UL97 kinase, developed for treatment of human cytomegalovirus infection in immunocompromised solid organ and bone marrow transplant recipients. Reported to be >5x more potent than Valcyte, active against resistant isolates, and non-genotoxic. Has completed Phase 1 clinical testing.
  • MBX-400 for Adenoviral Conjunctivitis Antiviral application of the MBX-400 platform targeting adenoviral conjunctivitis, including epidemic keratoconjunctivitis, where no approved antiviral therapy currently exists. Demonstrates broad-spectrum efficacy against multiple adenoviral serotypes and is in preclinical development.
  • Spectinamides Novel semisynthetic spectinomycin analogs that inhibit bacterial protein synthesis by binding to a unique site on the 30S ribosome, developed for narrow-spectrum treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. Demonstrated efficacy in multiple in vivo TB infection models.
  • Aminospectinomycins Novel spectinomycin derivatives with improved potency against Gram-negative and Gram-positive species, including drug-resistant clinical pathogens such as Neisseria gonorrhoeae and Chlamydia trachomatis, plus biodefense pathogens. Resistance mutants arise at very low frequency (~10^-11) and no cross-resistance is observed against existing protein synthesis inhibitors.
  • Type III Secretion System (T3SS) Inhibitors Novel anti-virulence small molecules targeting PscF in the Type III Secretion System of Pseudomonas aeruginosa. Reverses pathogen disruption of host innate immune response and is not subject to efflux or existing antibiotic resistance mechanisms. Being developed for prevention and treatment of ventilator-associated pneumonia in critically ill patients.
  • Trans-translation Inhibitors Broad-spectrum Gram-positive and Gram-negative antibacterial candidates that target the trans-translation pathway, a mechanism conserved across >99.9% of sequenced bacterial genomes and absent in metazoans. Demonstrated in vitro and in vivo activity against MRSA, Neisseria gonorrhoeae, Mycobacterium tuberculosis, and Francisella tularensis.
  • Efflux Pump Inhibitors (Pyranopyridines) Novel pyranopyridine RND-type efflux pump inhibitors designed to be used in combination with FDA-approved antibiotics to increase antibacterial potency and decrease resistance mutations in Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE).

Quantifiable outcome

  • MBX-400 demonstrated >5x more potent than current gold standard therapy (Valcyte) for CMV treatment
  • +5 more outcomes

Companies that use Microbiotix

Customer profile

Segments3 records

Ideal customer profiles2 records

Microbiotix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Microbiotix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AMR CentrecoreStrategic or Co-development PartnerThe AMR Centre is a key part of the UK's response to the global threat from antimicrobial resistance. Based at Alderley Park, the AMR Centre is a joint private-public initiative supporting the development of new antibiotics and diagnostics through a fully integrated development capability from pre-clinical hits through clinical proof of concept. Microbiotix and the AMR Centre combined resources and antimicrobial R&D expertise to accelerate development of Microbiotix's lead bacterial anti-virulence candidate targeting drug-resistant P. aeruginosa in critically ill pneumonia patients.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Microbiotix competitors and assessment

Company assessment

Direct peers

  • Cidara Therapeutics: Clinical-stage biopharmaceutical company developing anti-infectives, including antivirals and antifungal agents. Comparable as a small-cap private/clinical anti-infective developer pursuing novel mechanisms against serious infections, with similar funding-stage profile.
  • Paratek Pharmaceuticals: Specialty anti-infective developer focused on tetracycline-class antibiotics for serious community-acquired infections. Comparable as a small-cap clinical-stage antibiotic developer targeting multi-drug resistant pathogens, with overlapping federal funding and NIH grant relationships.
  • Nabriva Therapeutics: Clinical-stage biopharma developing antibiotics for serious and life-threatening infections, including MDR pathogens. Directly comparable as a small anti-infective company with a clinical-stage pipeline targeting resistant bacterial infections.
  • Iterum Therapeutics: Clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, including oral antibiotics for complicated UTIs. Comparable in therapeutic area (MDR infections), stage, and small-cap funding model.
  • Entasis Therapeutics: Clinical-stage biopharmaceutical company developing differentiated antibiotics for drug-resistant Gram-negative infections. Directly comparable as a focused anti-infective developer with a similar target pathogen profile (CRE, MDR Pseudomonas).
  • VenatoRx Pharmaceuticals: Private clinical-stage biopharmaceutical company developing novel antibiotics to treat MDR Gram-negative infections. Comparable in therapeutic focus (MDR bacterial infections), company stage, and BARDA-funded development model.
  • Tetraphase Biosciences: Clinical-stage biopharmaceutical company that developed eravacycline, a fluorocycline antibiotic for MDR infections (now part of Innoviva). Comparable as a historical peer in clinical-stage antibiotic development targeting serious multi-drug resistant infections.
  • Melinta Therapeutics: Commercial-stage anti-infective company that developed antibiotics for MDR bacterial infections before restructuring. Comparable as a historical peer in the antibiotic development space targeting MDR pathogens, illustrating both the opportunity and the structural commercial challenges.
  • Summit Therapeutics: Clinical-stage biopharmaceutical company developing ridinilazole for C. difficile infection and other anti-infective candidates. Comparable as a clinical-stage anti-infective developer focused on novel mechanisms against serious bacterial infections.
  • Achaogen: Former commercial-stage antibiotic developer (plazomicin for CRE) that filed for bankruptcy post-approval. Comparable as a historical direct peer that pursued a similar MDR Gram-negative pathogen strategy and illustrates the commercial risks facing Microbiotix's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Microbiotix social profiles

Digital presence

Microbiotix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microbiotix leadership team

Management profile

Number of profiles

Profiles3 records

Microbiotix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microbiotix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbiotix

What does Microbiotix do?

Microbiotix discovers and develops proprietary small molecule therapeutics for serious infectious diseases, with a pipeline that includes MBX-400 (filociclovir) for human cytomegalovirus, antibacterial programs (Spectinamides, Aminospectinomycins) for drug-resistant tuberculosis and gonorrhea, T3SS inhibitors for Pseudomonas aeruginosa, trans-translation inhibitors with broad-spectrum activity, and RND efflux pump inhibitors for Enterobacteriaceae. The company is pre-revenue and supports development primarily through grant funding from NIAID/NIH, CARB-X, and the U.S. Department of Defense.

Is Microbiotix a public or private company?

Microbiotix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Microbiotix founded?

Microbiotix was founded in 1998. It employs 11 to 50 people.

Where is Microbiotix based?

Microbiotix is headquartered in Worcester, United States, in the North America region.

Who are Microbiotix's main competitors?

Direct peers on record are Cidara Therapeutics, Paratek Pharmaceuticals, Nabriva Therapeutics, Iterum Therapeutics, Entasis Therapeutics, VenatoRx Pharmaceuticals, Tetraphase Biosciences, Melinta Therapeutics, Summit Therapeutics and Achaogen.

Does Microbiotix have an API?

No public API is recorded for Microbiotix.

What industry is Microbiotix in?

Microbiotix's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterMicrobiotix gets funding to develop multi-drug-resistant gonorrhoea therapyMicrobiotix received up to $2.86 million in non-dilutive funding from CARB-X to develop an oral antibiotic for multidrug-resistant gonorrhea. The company may qualify for an additional $16 million if it reaches certain development milestones.PR NewswireGlobal Swine and Avian Influenza Drug Development Pipeline Review 2017 Featuring Gemmus Pharma, Aphios, Fides Pharma, Inovio, Microbiotix, NanoViricides, Shionogi and Tria BioscienceResearchAndMarkets.com published a market report in February 2018 providing an overview of the swine and avian influenza drug development pipeline as of 2017. The report found 63 products in development for H5N1 (avian influenza) by 47 companies and 6 academic institutions, and 99 products in development for H1N1 (swine flu) by 67 companies and 14 academic institutions.PR NewswireMicrobiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia PatientsMicrobiotix, Inc. and the AMR Centre announced a co-development agreement to accelerate the development of Microbiotix's T3SS (type III secretion system) inhibitor project targeting drug-resistant P. aeruginosa in critically ill pneumonia patients. The AMR Centre will provide up to $1.1 million in technical support and project funding, combining with $1.6 million in initial CARB-X funding, to identify a drug candidate for clinical trials. The novel T3SS inhibitors address the infection's effects without directly killing the organism, potentially avoiding the development of antibiotic resistance.